National Cancer Institute, Research Contracts Branch, PSAS, 6120 Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227

A -- RESEARCH & DEVELOPMENT SOL RFQ-NCI-0032 DUE 011700 POC Cynthia Brown, Purchasing Agent, 301-402-4509, Todd Cole, Contracting Officer The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG),Genetic Epidemiology Branch (GEB) plans to procure services from the Division of Research in Environment and Human Development of the International Fertility Institute, 142 Achuza Street, 43300 Ra'anana, Israel. The Division of Cancer Epidemiology and Genetics has a requirement to define the risk of prostate cancer associated with carrying mutations in the cancer susceptibility genes BRCA1 and BRCA2. The NCI's interest is an outgrowth of ongoing research in the Genetic Epidemiology Branch where previous studies in the Jewish community of greater Washington, DC have suggested an increased prostate cancer risk associated with BRCA1 and BRCA2 founder mutations common within this ethnic group. The purpose of this procurement is to obtain demographic and clinical data and pathology tumor tissue from an available sample of approximately 1,000 Ashkenazi men with incident prostate cancer or with prostatic intraepithelial neoplasis (PIN) that were diagnosed between 1994 and 1995. This sample represents an estimated two-thirds of all Ashkenazi men that were diagnosed with prostate cancer in Israel during this time. These data are especially important since sixty percent of Israeli Jewish men over 60 years of age are of Ashkenazi ethnicity. The data will provide age specific estimates of mutation prevalance and enable NCI to obtain pathology data from approximately 30 BRCA1 and BRCA2 associated prostate cancers. These data will benefit GEB's overall study to refine estimates of the prevalence of BRCA1/BRCA2 mutations among Ashkenazi Jews with prostate cancer, including rates among men with early as compared to late onset prostate cancer, and to analyze pathologic characteristics of a larger group of BRCA1 and BRCA2 associated prostate cancers through review of incident prostate cancer among the sample of Ashkenazi Jews. Dr. Iscovich, who works at the International Fertility Institute (IFI) is an internationally known cancer research who has worked at the Israeli Cancer Registry and other research institutions. He has extensive experience in collaborating with such efforts. Dr. Iscovich is intimately familiar with the policies and procedures of the tumor registry and with the approval process to collect pathologic material from hospital pathology departments in Israel. IFI, combined with Dr. Iscovich's expertise, enable efficient collection of the aforementioned data. For example, under a previous study, IFI and Dr. Iscovich collected 250 male breast cancer samples that were successfully linked to the Israeli population registry. There is no other known source known by the NCI researcher that can perform the above requirement. This is not a request for competitive quotation. However, if any interested party believes it can provide the above services and has significant experience in the aforementioned research and data collection, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI researcher to determine if the party can provide the above services and access to a similar sample (All collection and data shall be provided within six months of award). Capability statements must be received in the contracting office by 2:00 p.m. (Local Time) on January 17, 2000 If you have any questions, please contact Cynthia Brown, Purchasing Agent on (301) 402-4509. A determination by the government not to compete this requirement based upon responses to this notice is solely within the discretion of the government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Please reference RFQ-NCI-0032 on all correspondence and documentation. Posted 12/28/99 (W-SN411776). (0362)

Loren Data Corp. http://www.ld.com (SYN# 0002 19991230\A-0002.SOL)